major depressive disorder esketamine

FDA, major depressive disorder

FDA approves first-of-its-kind nasal spray for severe depression

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.

Hosted on MSN · 1d

FDA Expands Approval of Esketamine for Depression

The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an inadequate response to at least two oral antidepressants, maker Johnson & Johnson announced on Tuesday.

Healio · 1d

FDA approves Spravato as monotherapy for adults with major depressive disorder

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as monotherapy for adults with treatment-resistant depression, Johnson & Johnson announced in a press release.

IFLScience3h

FDA Approves First-Ever Standalone Therapy For Treatment-Resistant Depression

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...

Can Taking Antidepressants Cause Weight Loss?

If you’ve been diagnosed with major depressive disorder, seasonal affective depression or any other type of depression, your ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

FDA, major depressive disorder

Trending now